---
document_datetime: 2025-12-02 06:14:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/miglustat-dipharma.html
document_name: miglustat-dipharma.html
version: success
processing_time: 0.1335712
conversion_datetime: 2025-12-24 07:51:27.530136
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Miglustat Dipharma

[RSS](/en/individual-human-medicine.xml/67174)

##### Authorised

This medicine is authorised for use in the European Union

miglustat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Miglustat Dipharma](#news-on)
- [Mora information on Miglustat Dipharma](#mora-information-on-miglustat-dipharma-1552)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Miglustat Dipharma is used to treat two inherited diseases that affect the way the body handles fats. Both diseases cause a build-up of fatty substances called glycosphingolipids in the body. Miglustat Dipharma is used to treat the following patients:

- adults (aged 18 years and above) with mild to moderate type-1 Gaucher disease. Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones. Miglustat Dipharma is used in patients who cannot receive the standard treatment of enzyme- replacement therapy (ERT);
- patients of all ages with Niemann-Pick type-C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body. Miglustat Dipharma is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves). These include loss of coordination, problems with 'saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning

Miglustat Dipharma is a 'generic medicine'. This means that Miglustat Dipharma contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Zavesca.

Expand section

Collapse section

## How is Miglustat Dipharma used?

Miglustat Dipharma is available as 100 mg capsules to be taken by mouth. The recommended starting dose for type-1 Gaucher disease is one capsule three times a day. For Niemann-Pick type-C disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height. Miglustat Dipharma is intended for long-term use.

The medicine can only be obtained with a prescription and treatment should be supervised by doctors who are experienced in the management of Gaucher disease.

For more information about using Miglustat Dipharma, see the package leaflet or contact your doctor or pharmacist.

## How does Miglustat Dipharma work?

The active substance in Miglustat Dipharma, miglustat, blocks an enzyme called glucosylceramide synthase. This enzyme is involved in the first step of the production of glucosylceramide. By preventing the enzyme from working, miglustat can reduce the production of glucosylceramide in cells, thereby reducing the symptoms of type-1 Gaucher disease.

## How has Miglustat Dipharma been studied?

Studies on the benefits and risks of the active substance in Gaucher disease have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Miglustat Dipharma.

As for every medicine, the company provided studies on the quality of Miglustat Dipharma. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Miglustat Dipharma?

Because Miglustat Dipharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Miglustat Dipharma authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Miglustat Dipharma has been shown to have comparable quality and to be bioequivalent to Zavesca. Therefore, the Agency's view was that, as for Zavesca, the benefit of Miglustat Dipharma outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Miglustat Dipharma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Miglustat Dipharma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Miglustat Dipharma are continuously monitored. Side effects reported with Miglustat Dipharma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Miglustat Dipharma

Miglustat Dipharma received a marketing authorisation valid throughout the EU on 18 February 2019.

Miglustat Dipharma : EPAR - Medicine overview

Reference Number: EMA/335910/2019

English (EN) (80.47 KB - PDF)

**First published:** 02/05/2019

**Last updated:** 14/10/2019

[View](/en/documents/overview/miglustat-dipharma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-745)

български (BG) (108.69 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/bg/documents/overview/miglustat-dipharma-epar-medicine-overview_bg.pdf)

español (ES) (81.23 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/es/documents/overview/miglustat-dipharma-epar-medicine-overview_es.pdf)

čeština (CS) (103.83 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/cs/documents/overview/miglustat-dipharma-epar-medicine-overview_cs.pdf)

dansk (DA) (78.97 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/da/documents/overview/miglustat-dipharma-epar-medicine-overview_da.pdf)

Deutsch (DE) (81.96 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/de/documents/overview/miglustat-dipharma-epar-medicine-overview_de.pdf)

eesti keel (ET) (78.76 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/et/documents/overview/miglustat-dipharma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (117.51 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/el/documents/overview/miglustat-dipharma-epar-medicine-overview_el.pdf)

français (FR) (81.3 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/fr/documents/overview/miglustat-dipharma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (99.27 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/hr/documents/overview/miglustat-dipharma-epar-medicine-overview_hr.pdf)

italiano (IT) (80.4 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/it/documents/overview/miglustat-dipharma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (100.71 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/lv/documents/overview/miglustat-dipharma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (100.92 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/lt/documents/overview/miglustat-dipharma-epar-medicine-overview_lt.pdf)

magyar (HU) (101.72 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/hu/documents/overview/miglustat-dipharma-epar-medicine-overview_hu.pdf)

Malti (MT) (104.64 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/mt/documents/overview/miglustat-dipharma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (80.93 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/nl/documents/overview/miglustat-dipharma-epar-medicine-overview_nl.pdf)

polski (PL) (105 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/pl/documents/overview/miglustat-dipharma-epar-medicine-overview_pl.pdf)

português (PT) (80.9 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/pt/documents/overview/miglustat-dipharma-epar-medicine-overview_pt.pdf)

română (RO) (102.23 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/ro/documents/overview/miglustat-dipharma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (104.91 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/sk/documents/overview/miglustat-dipharma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (97.91 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/sl/documents/overview/miglustat-dipharma-epar-medicine-overview_sl.pdf)

Suomi (FI) (78.88 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/fi/documents/overview/miglustat-dipharma-epar-medicine-overview_fi.pdf)

svenska (SV) (80.47 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

14/10/2019

[View](/sv/documents/overview/miglustat-dipharma-epar-medicine-overview_sv.pdf)

## Product information

Miglustat Dipharma : EPAR - Product information

English (EN) (306.29 KB - PDF)

**First published:** 02/05/2019

**Last updated:** 25/06/2025

[View](/en/documents/product-information/miglustat-dipharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-282)

български (BG) (552.8 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/bg/documents/product-information/miglustat-dipharma-epar-product-information_bg.pdf)

español (ES) (415.08 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/es/documents/product-information/miglustat-dipharma-epar-product-information_es.pdf)

čeština (CS) (427.15 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/cs/documents/product-information/miglustat-dipharma-epar-product-information_cs.pdf)

dansk (DA) (309.34 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/da/documents/product-information/miglustat-dipharma-epar-product-information_da.pdf)

Deutsch (DE) (332.09 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/de/documents/product-information/miglustat-dipharma-epar-product-information_de.pdf)

eesti keel (ET) (329.17 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/et/documents/product-information/miglustat-dipharma-epar-product-information_et.pdf)

ελληνικά (EL) (413.21 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/el/documents/product-information/miglustat-dipharma-epar-product-information_el.pdf)

français (FR) (324.52 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/fr/documents/product-information/miglustat-dipharma-epar-product-information_fr.pdf)

hrvatski (HR) (389.37 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/hr/documents/product-information/miglustat-dipharma-epar-product-information_hr.pdf)

íslenska (IS) (303.9 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/is/documents/product-information/miglustat-dipharma-epar-product-information_is.pdf)

italiano (IT) (310.69 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/it/documents/product-information/miglustat-dipharma-epar-product-information_it.pdf)

latviešu valoda (LV) (391.64 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/lv/documents/product-information/miglustat-dipharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (400.69 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/lt/documents/product-information/miglustat-dipharma-epar-product-information_lt.pdf)

magyar (HU) (417.89 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/hu/documents/product-information/miglustat-dipharma-epar-product-information_hu.pdf)

Malti (MT) (435.07 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/mt/documents/product-information/miglustat-dipharma-epar-product-information_mt.pdf)

Nederlands (NL) (316.62 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/nl/documents/product-information/miglustat-dipharma-epar-product-information_nl.pdf)

norsk (NO) (317.57 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/no/documents/product-information/miglustat-dipharma-epar-product-information_no.pdf)

polski (PL) (395.3 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/pl/documents/product-information/miglustat-dipharma-epar-product-information_pl.pdf)

português (PT) (360.52 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/pt/documents/product-information/miglustat-dipharma-epar-product-information_pt.pdf)

română (RO) (530.94 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/ro/documents/product-information/miglustat-dipharma-epar-product-information_ro.pdf)

slovenčina (SK) (415.66 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/sk/documents/product-information/miglustat-dipharma-epar-product-information_sk.pdf)

slovenščina (SL) (408.92 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/sl/documents/product-information/miglustat-dipharma-epar-product-information_sl.pdf)

Suomi (FI) (302.03 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/fi/documents/product-information/miglustat-dipharma-epar-product-information_fi.pdf)

svenska (SV) (319.94 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

25/06/2025

[View](/sv/documents/product-information/miglustat-dipharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000263310 16/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Miglustat Dipharma : EPAR - All authorised presentations

English (EN) (20.29 KB - PDF)

**First published:** 02/05/2019

**Last updated:** 26/07/2023

[View](/en/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-110)

български (BG) (48.18 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/bg/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.29 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/es/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.14 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/cs/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (20.31 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/da/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.39 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/de/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.33 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/et/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.66 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/el/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_el.pdf)

français (FR) (20.28 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/fr/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (44.25 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/hr/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (20.3 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/is/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (20.53 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/it/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (42.85 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/lv/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.17 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/lt/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.1 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/hu/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.33 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/mt/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (20.63 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/nl/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (20.37 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/no/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.1 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/pl/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.05 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/pt/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (40.63 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/ro/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (41.23 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/sk/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.23 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/sl/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.61 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/fi/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.27 KB - PDF)

**First published:**

02/05/2019

**Last updated:**

26/07/2023

[View](/sv/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Miglustat Dipharma Active substance miglustat International non-proprietary name (INN) or common name miglustat Therapeutic area (MeSH) Gaucher Disease Anatomical therapeutic chemical (ATC) code A16AX06

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.

Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.

Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.

## Authorisation details

EMA product number EMEA/H/C/004904

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Dipharma Arzneimittel GmbH

Offheimer Weg 33

Opinion adopted 13/12/2018 Marketing authorisation issued 18/02/2019 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Miglustat Dipharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.42 KB - PDF)

**First published:** 25/06/2025

[View](/en/documents/procedural-steps-after/miglustat-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Miglustat Dipharma : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (166.64 KB - PDF)

**First published:** 14/10/2019

**Last updated:** 25/06/2025

[View](/en/documents/procedural-steps-after/miglustat-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Miglustat Dipharma : EPAR - Public assessment report

Adopted

Reference Number: EMA/219798/2019

English (EN) (271.41 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/assessment-report/miglustat-dipharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Miglustat Dipharma

Adopted

Reference Number: EMA/CHMP/825267/2018

English (EN) (62.37 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-miglustat-dipharma_en.pdf)

#### News on Miglustat Dipharma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

#### Mora information on Miglustat Dipharma

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/06/2025

## Share this page

[Back to top](#main-content)